Janssen Research & Development was granted FDA orphan designation for its selective inhibitor of mechanistic target of rapamycin complex 1 for the treatment of autosomal Dominant Polycystic Kidney Disease, or ADPKD, according to a post to the agency’s website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- AC Immune reports ACI-35.030 advances into Phase 2b trial
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
- Protagonist earns $10M payment for milestone in Phase 2b ANTHEM-UC study
- Integra to acquire Acclarent from Johnson & Johnson for $275M